Avnish Kapoor
About Avnish Kapoor
Avnish Kapoor is the Executive Director of Oncology Business Development at Bristol Myers Squibb in Cambridge, MA, specializing in search and evaluation in oncology.
Title and Current Role
Avnish Kapoor serves as the Executive Director of Oncology Business Development at Bristol Myers Squibb in Cambridge, Massachusetts. In his role, he is responsible for overseeing oncology business development initiatives with a focus on search and evaluation across all oncology thematic research centers and stages of development.
Previous Roles and Experience
Before his current position, Avnish Kapoor held various notable roles in oncology and biomedical research. He was Senior Director of Oncology Business Development at Bristol Myers Squibb for 8 months in Cambridge and Senior Director of Strategy and Partnering at BeiGene for 6 months. He also worked at Eli Lilly and Company for several years, holding positions such as Director of Venture Sciences and Principal Research Scientist in Discovery Oncology.
Educational Background
Avnish Kapoor holds a Doctor of Philosophy (PhD) in Biomedical Sciences from the Icahn School of Medicine at Mount Sinai, obtained between 2006 and 2011. Additionally, he earned a Master of Science (MS) in Molecular Biology from Delhi University and another MS from the University of Arizona. His strong educational foundation supports his extensive work in oncology and biomedical research.
Research and Postdoctoral Work
Avnish Kapoor has an extensive background in research and postdoctoral work. He was a Jane Coffin Childs Postdoctoral Fellow at MD Anderson Cancer Center from 2011 to 2014 and a Postdoctoral Fellow at Icahn School of Medicine at Mount Sinai in 2011. He also served as a Graduate Research Assistant at the University of California, Riverside, from 2003 to 2006.
Specializations and Expertise
Specializing in oncology search and evaluation, Avnish Kapoor has significant expertise in precision medicine, genomic medicine, DNA/RNA editing, and gene therapy. His experience spans multiple high-impact roles in leading biomedical research institutions and pharmaceutical companies, emphasizing his deep knowledge and strategic insight in oncological research and development.